LAVIOR

What LAVIOR does

LAVIOR (legally Lavior Pharma, Inc.) is a privately held, Florida-incorporated company that develops and sells a focused line of botanical-based topical wound care and skin barrier products, anchored on a proprietary ingredient derived from the Inula viscosa AGS-RIED species. The company was founded in 2013 with headquarters in Miami and an operating office in Hallandale Beach, FL, and positions itself as the only brand exclusively dedicated to a comprehensive line of diabetic wound and skin treatments. Its product portfolio consists of seven SKUs across two lines — a diabetic-specific range (Diabetic Wound Therapy Gel, Diabetic First Aid Gel, Diabetic Skin Barrier Cream, Diabetic Wound Dressing) and a general-purpose range (Multipurpose Wound Gel, Post-Surgical Skin Barrier Gel) — all formulated around the same Inula viscosa AGS-RIED extract, priced between $17.95 and $50.00, and supported by a peer-reviewed clinical study published in the Journal of Wound Care.

The underlying technology platform is a botanical formulation IP stack rather than a software or device platform: 16 years of research into the Inula viscosa AGS-RIED species, FDA-registered OTC product status, and a small clinical evidence base demonstrating superior wound surface area reduction and pain reduction versus competing treatments in a 65-patient diabetic study. The company has no disclosed patents, no SDK/API surface, and no AI/ML components; its digital infrastructure is a Shopify storefront with multi-language (8 languages) and multi-currency checkout, plus subscription billing and HSA/FSA payment acceptance.

LAVIOR operates a direct-to-consumer e-commerce go-to-market via lavior.com, targeting three customer segments: diabetic patients (primary, including foot ulcer and amputation-prevention use cases), general consumers seeking everyday wound and skin care, and healthcare clinicians (podiatrists and wound care specialists) reached through a dedicated site section and two VP-of-Sales hires. Revenue is generated through one-time product purchases and recurring subscriptions; distribution is global in claim (international shipping) but concentrated on the company's own website with no disclosed retail, hospital, or third-party distributor channels. Media presence includes coverage on ABC, NBC, CBS, Fox News, and The CW.

Name

LAVIOR

Legal name

Lavior Pharma, Inc.

Website

https://lavior.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

LAVIOR (Lavior Pharma, Inc.) is a Florida-based, privately held company that sells a botanical wound care and skin barrier product line built on a proprietary Inula viscosa AGS-RIED formulation, targeting diabetic patients, everyday consumers, and clinicians through direct-to-consumer e-commerce with subscriptions and HSA/FSA payments.

Ownership category

akta.pro rank

Product category

Diabetic Wound Care

NAICS

Health and Personal Care Retailers (456), Cosmetics, Beauty Supplies, and Perfume Retailers (45612)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844), Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics (2840)

akta.pro primary industry

Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

akta.pro secondary industries

Sensitive Skin & Barrier Repair (CRABAAAG), Antibacterial & Medicated Cleansers (e.g., Acne, Antifungal, Antiseptic) (CRABAEAH)

Keywords

• Diabetic wound care
• Botanical skincare products
• Hydrogel wound dressing
• Skin barrier cream
• Diabetic skin therapy

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Technology or R&D, Personnel, Operations

Revenue model

1. Product Sales: Direct e-commerce sales of botanical wound care products including diabetic wound therapy gel, multipurpose wound gel, post-surgical skin barrier gel, diabetic first aid gel, and diabetic skin barrier cream. Products sold as one-time purchases or through subscription plans.
2. Subscription Model: Recurring subscription purchases for ongoing product needs, particularly targeting chronic diabetic wound care patients who require continuous product usage.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

LAVIOR develops, manufactures, and sells a botanical-based skincare and wound care product line formulated for diabetic skin conditions and general wound care. The portfolio is built on a proprietary Inula viscosa AGS-RIED botanical extract and includes wound gels, hydrogels, post-surgical skin barrier gels, diabetic first aid gel, and skin barrier creams sold directly to consumers via lavior.com.

Product overview

LAVIOR is a US-based pharmaceutical company exclusively dedicated to botanical-based diabetic wound and skin care products. The product portfolio is built on 16 years of research using the Inula viscosa AGS-RIED species combined with scientific expertise. The core offerings include the Diabetic Wound Therapy Gel, Diabetic Wound Dressing (hydrogel formulation), Diabetic First Aid Gel, and Diabetic Skin Barrier Cream for the diabetic care line, alongside the Multipurpose Wound Gel and Post-Surgical Skin Barrier Gel for general wound care. All products are sold as topical gel/cream formulations in 1oz and 3.4oz sizes, positioned as clinically backed botanical alternatives to traditional wound care treatments. Products are available for purchase directly through the company's e-commerce platform at lavior.com and accept HSA/FSA payments.

Differentiator

Problem solved

Functional benefit

Products and services

• Diabetic Wound Therapy Gel - 1oz Botanical-based wound dressing specifically formulated for diabetic wound care, featuring Inula viscosa AGS-RIED species extract; priced at $23.95 (sale price $19.95). Targeted at diabetic patients and consumers needing wound therapy.
• Multipurpose Wound Gel - 1oz
• Post-Surgical Skin Barrier Gel - 1oz
• Diabetic First Aid Gel - 1oz
• Diabetic Skin Barrier Cream - 3.4oz

Quantifiable outcome

• Greater reduction in wound surface area compared to competing treatment in peer-reviewed study (Journal of Wound Care)
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Organogenesis: Organogenesis is a regenerative medicine company offering skin substitutes and advanced wound care biologics (Apligraf, Dermagraft). It competes in the higher-acuity diabetic wound care segment that LAVIOR's clinical evidence could position it against.
• MiMedx: MiMedx is a regenerative medicine company focused on placental tissue allografts for wound healing and skin recovery. It represents an emerging, more clinical-grade competitor in advanced diabetic wound care.

Broad incumbents

• Smith & Nephew: Smith & Nephew is a global medical device leader with a significant Advanced Wound Management portfolio, including hydrogel and antimicrobial dressings that compete with LAVIOR's wound therapy gels in clinical settings.
• CeraVe (L'Oréal): CeraVe is a mass-market dermocosmetic brand focused on ceramides, barrier repair, and sensitive/dry skin — overlapping directly with LAVIOR's skin barrier positioning for diabetic and sensitive skin.
• Coloplast: Coloplast develops wound care, ostomy, and skin care products for chronic conditions, including diabetic-friendly skin barriers and hydrocolloid dressings. It is a key incumbent in the same clinician-driven wound care category LAVIOR targets.
• ConvaTec: ConvaTec is a major wound care and ostomy company offering hydrogel dressings, skin barriers, and advanced wound therapies — directly overlapping with LAVIOR's wound gel and barrier cream product lines in the clinician channel.
• 3M Health Care (Solventum): 3M's health care business (now Solventum) is a dominant wound care and skin integrity player, offering hydrogel dressings and skin protectants that overlap with LAVIOR's diabetic and post-surgical barrier products.
• Cetaphil (Galderma): Cetaphil is a long-established sensitive-skin skincare brand frequently recommended by dermatologists and podiatrists for diabetic patients. It competes with LAVIOR's barrier cream and everyday wound gel in the OTC consumer channel.
• La Roche-Posay (L'Oréal): La Roche-Posay is a dermocosmetic brand widely recommended for sensitive, post-procedure, and compromised skin, including diabetic skin. Its Cicaplast and Lipikar lines overlap with LAVIOR's barrier and post-surgical gel products.

Direct peers

• Neoteric Diabetic Skin Care (Crown Laboratories): Neoteric Diabetic Skin Care is an OTC brand specifically formulated for diabetic skin, including foot creams and therapeutic skincare. It is the closest direct competitor to LAVIOR in the diabetic-focused skin care niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/laviorskincare
• Facebookfacebook.com/Laviorskincare

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LAVIOR